JP2024523506A5 - - Google Patents
Info
- Publication number
- JP2024523506A5 JP2024523506A5 JP2023579154A JP2023579154A JP2024523506A5 JP 2024523506 A5 JP2024523506 A5 JP 2024523506A5 JP 2023579154 A JP2023579154 A JP 2023579154A JP 2023579154 A JP2023579154 A JP 2023579154A JP 2024523506 A5 JP2024523506 A5 JP 2024523506A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- diffraction pattern
- ray powder
- powder diffraction
- crystalline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163214089P | 2021-06-23 | 2021-06-23 | |
| US63/214,089 | 2021-06-23 | ||
| PCT/US2022/034550 WO2022271846A1 (en) | 2021-06-23 | 2022-06-22 | Salt and crystal forms of an epidermal growth factor receptor inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024523506A JP2024523506A (ja) | 2024-06-28 |
| JP2024523506A5 true JP2024523506A5 (enExample) | 2025-06-30 |
Family
ID=82608408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023579154A Pending JP2024523506A (ja) | 2021-06-23 | 2022-06-22 | 上皮成長因子受容体阻害剤の塩及び結晶形態 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240293404A1 (enExample) |
| EP (1) | EP4359400B1 (enExample) |
| JP (1) | JP2024523506A (enExample) |
| CN (1) | CN117836287A (enExample) |
| CA (1) | CA3223859A1 (enExample) |
| ES (1) | ES3042447T3 (enExample) |
| IL (1) | IL309469A (enExample) |
| TW (1) | TW202317543A (enExample) |
| WO (1) | WO2022271846A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3213079A1 (en) | 2021-04-13 | 2022-10-20 | Kristin Lynne ANDREWS | Amino-substituted heterocycles for treating cancers with egfr mutations |
| IL309447A (en) * | 2021-06-23 | 2024-02-01 | Blueprint Medicines Corp | Pharmaceutical preparations of epidermal growth factor receptor inhibitor |
| CN116554150B (zh) * | 2022-12-30 | 2025-12-19 | 苏州浦合医药科技有限公司 | 第四代egfr抑制剂 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI726968B (zh) * | 2016-01-07 | 2021-05-11 | 開曼群島商Ｃｓ醫藥技術公司 | Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑 |
| JP7752617B2 (ja) * | 2019-12-23 | 2025-10-10 | ブループリント メディシンズ コーポレイション | Ｅｇｆｒの変異型の阻害剤 |
| US20240058340A1 (en) * | 2020-09-21 | 2024-02-22 | The Regents Of The University Of California | Compositions and methods for treating cancer |
| IL309447A (en) * | 2021-06-23 | 2024-02-01 | Blueprint Medicines Corp | Pharmaceutical preparations of epidermal growth factor receptor inhibitor |
| CN117881670A (zh) * | 2021-06-23 | 2024-04-12 | 缆图药品公司 | 制备egfr抑制剂的方法 |
-
2022
- 2022-06-22 JP JP2023579154A patent/JP2024523506A/ja active Pending
- 2022-06-22 ES ES22744048T patent/ES3042447T3/es active Active
- 2022-06-22 TW TW111123214A patent/TW202317543A/zh unknown
- 2022-06-22 US US18/573,222 patent/US20240293404A1/en active Pending
- 2022-06-22 WO PCT/US2022/034550 patent/WO2022271846A1/en not_active Ceased
- 2022-06-22 CA CA3223859A patent/CA3223859A1/en active Pending
- 2022-06-22 EP EP22744048.4A patent/EP4359400B1/en active Active
- 2022-06-22 IL IL309469A patent/IL309469A/en unknown
- 2022-06-22 CN CN202280057121.2A patent/CN117836287A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105209437B (zh) | 心肌肌球蛋白激动剂的盐和制备盐的方法 | |
| JP6918824B2 (ja) | ２−［（２Ｓ）−１−アザビシクロ［２．２．２］オクタ−２−イル］−６−（３−メチル−１Ｈ−ピラゾール−４−イル）チエノ［３，２−ｄ］ピリミジン−４（３Ｈ）−オン半水和物の結晶形 | |
| JP2020517611A5 (enExample) | ||
| CN1227233C (zh) | 纯晶形的5－氯－3－(4－甲磺酰基苯基)－6′－甲基－[2,3′]联吡啶及其合成方法 | |
| KR102142796B1 (ko) | 피리디닐아미노피리미딘 유도체의 염, 그의 제조 방법, 및 그의 용도 | |
| US9630952B2 (en) | Crystalline forms of afatinib di-maleate | |
| JP2008543974A (ja) | ペメトレキセド二酸の結晶形およびその調製方法 | |
| TW201731812A (zh) | 用於製備喹啉衍生物之方法 | |
| JP6830888B2 (ja) | Ｊａｋ阻害剤の硫酸水素塩の結晶形およびその製造方法 | |
| JP2003523334A (ja) | ７−［４−（４−フルオロフェニル）−６−イソプロピル−２−［メチル（メチルスルホニル）アミノ］ピリミジン−５−イル］−（３ｒ，５ｓ）−３，５−ジヒドロキシ−６−ヘプテン酸の結晶性塩 | |
| JP2021522335A5 (enExample) | ||
| WO2023174400A1 (zh) | 一种取代的氨基六元氮杂环类化合物的盐及其晶型、制备方法和应用 | |
| CN111825700A (zh) | 一种吡嗪并噻唑类化合物、其应用及含其的药物组合物 | |
| CN114716377A (zh) | 吡唑-酰胺化合物的制造方法 | |
| CN112119074A (zh) | Egfr抑制剂 | |
| JP4904561B2 (ja) | アザビシクロオクタン−３−オン誘導体及びその使用 | |
| JP2004530706A (ja) | 純粋な結晶形態にある５−クロロ−３−（４−メタンスルホニルフェニル）−６’−メチル−［２，３’］ビピリジニル及び合成方法 | |
| TWI551603B (zh) | 培美曲塞二酸之晶型及其製備方法 | |
| JP6594333B2 (ja) | Ｈｘ塩の形態の（ｅ）−４−ｎ，ｎ−ジアルキルアミノクロトン酸の製造方法、およびｅｇｆｒチロシンキナーゼ阻害剤の合成のためのその使用 | |
| CN108419436B (zh) | 一种取代的吡嗪甲酰胺类化合物及包含该化合物的组合物及其用途 | |
| JP2022531571A (ja) | ジアミノピリミジン化合物の塩、及びその固体形態、その調製方法及びその使用 | |
| JP2025517634A5 (enExample) | ||
| CN102272126B (zh) | 光学纯喹唑啉类化合物 | |
| WO2012125993A1 (en) | Solid state forms of rilpivirine base, and rilipivirine salts | |
| JP6871255B2 (ja) | ゲフィチニブの結晶形ａを製造する方法 |